Jonathan W. Ayers - 06 May 2024 Form 4 Insider Report for IDEXX LABORATORIES INC /DE (IDXX)

Reporting relationship: Director
Issuer ticker: IDXX
Reported as of: 06 May 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 May 2024, 19:00:14 UTC
Prior SEC filing: 12 Feb 2024
Next SEC filing: 09 Sep 2024
Source filing: View source filing
Reporting owner signature: /s/ Lily J. Lu, Attorney-in-Fact for Jonathan W. Ayers

Key filing fact

Jonathan W. Ayers filed Form 4 for IDEXX LABORATORIES INC /DE (IDXX) on 08 May 2024.

Key facts

This page summarizes Jonathan W. Ayers's Form 4 filing for IDEXX LABORATORIES INC /DE (IDXX).
4 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 08 May 2024, 19:00.

Change

Previous filing in this sequence was filed on 12 Feb 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IDXX transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +257
Change %: +0.1%
Price: $0.000000
Shares after: 265,651
Date: 06 May 2024
Ownership: Direct

IDXX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 302,179
Date: 06 May 2024
Ownership: by Jonathan W. Ayers 2022 GRAT
Footnotes: F1

IDXX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 10,000
Date: 06 May 2024
Ownership: by Ayers Family Trust

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IDXX transaction Derivative

Non-Qualified Stock Option (right-to-buy)

Award

Transaction value: $0
Shares: +609
Change %
Price: $0.000000
Shares after: 609
Date: 06 May 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 609
Exercise price: $476.87
Footnotes: F2

IDXX transaction Derivative

Restricted Stock Unit

Award

Transaction value: $0
Shares: +262
Change %
Price: $0.000000
Shares after: 262
Date: 06 May 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 262
Exercise price
Footnotes: F3

IDXX transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value: $0
Shares: -257
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 06 May 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 257
Exercise price
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The reporting person is the grantor and trustee of the Jonathan W. Ayers 2022 GRAT (the 'GRAT'). The GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

Footnote F2

Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier.

Footnote F3

Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier.

Footnote F4

Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event was earlier.